142 related articles for article (PubMed ID: 22966362)
1. Octreotide acetate enables the administration of chemoradiotherapy, including the oral anticancer drug S-1, in gastric cancer patients with malignant gastrointestinal obstruction.
Takahashi T; Saikawa Y; Igarashi T; Tsuwano S; Kumagai K; Nakamura R; Ooyama T; Wada N; Takeuchi H; Takaishi H; Kitagawa Y
Oncol Lett; 2010 Jul; 1(4):673-677. PubMed ID: 22966362
[TBL] [Abstract][Full Text] [Related]
2. Octreotide acetate successfully treated a bowel obstruction caused by peritoneally disseminated gastric cancer, thereby enabling the subsequent use of oral S-1 chemotherapy.
Kumagai K; Saikawa Y; Fukuda K; Ito R; Igarashi T; Tsuwano S; Nakamura R; Takahashi T; Takeuchi H; Kitagawa Y
Int J Clin Oncol; 2009 Aug; 14(4):372-5. PubMed ID: 19705252
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction.
Shima Y; Ohtsu A; Shirao K; Sasaki Y
Jpn J Clin Oncol; 2008 May; 38(5):354-9. PubMed ID: 18490369
[TBL] [Abstract][Full Text] [Related]
4. Palliative Chemotherapy: Does It Only Provide False Hope? The Role of Palliative Care in a Young Patient With Newly Diagnosed Metastatic Adenocarcinoma.
Doverspike L; Kurtz S; Selvaggi K
J Adv Pract Oncol; 2017; 8(4):382-386. PubMed ID: 30018843
[No Abstract] [Full Text] [Related]
5. Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer.
Kubota H; Taguchi K; Kobayashi D; Naruyama H; Hirose M; Fukuta K; Kubota Y; Yasui T; Yamada Y; Kohri K
Asian Pac J Cancer Prev; 2013; 14(12):7107-10. PubMed ID: 24460259
[TBL] [Abstract][Full Text] [Related]
6. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction.
Hisanaga T; Shinjo T; Morita T; Nakajima N; Ikenaga M; Tanimizu M; Kizawa Y; Maeno T; Shima Y; Hyodo I
Jpn J Clin Oncol; 2010 Aug; 40(8):739-45. PubMed ID: 20410056
[TBL] [Abstract][Full Text] [Related]
7. The role of somatostatin and octreotide in bowel obstruction: pre-clinical and clinical results.
Ripamonti C; Panzeri C; Groff L; Galeazzi G; Boffi R
Tumori; 2001; 87(1):1-9. PubMed ID: 11669548
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04-.
Matsuda S; Takahashi T; Fukada J; Fukuda K; Kawakubo H; Saikawa Y; Kawaguchi O; Takeuchi H; Shigematsu N; Kitagawa Y
Radiat Oncol; 2014 Jan; 9():9. PubMed ID: 24398302
[TBL] [Abstract][Full Text] [Related]
9. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.
Mercadante S; Ripamonti C; Casuccio A; Zecca E; Groff L
Support Care Cancer; 2000 May; 8(3):188-91. PubMed ID: 10789958
[TBL] [Abstract][Full Text] [Related]
10. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction.
Mercadante S; Spoldi E; Caraceni A; Maddaloni S; Simonetti MT
Palliat Med; 1993; 7(4):295-9. PubMed ID: 7505187
[TBL] [Abstract][Full Text] [Related]
11. Survival analysis of a prospective multicenter observational study on surgical palliation among patients with malignant bowel obstruction caused by peritoneal dissemination of gastric cancer.
Kawabata R; Fujitani K; Sakamaki K; Ando M; Ito Y; Tanizawa Y; Yamada T; Hirao M; Yamada M; Hihara J; Ryoji ; Fukushima ; Choda Y; Kodera Y; Teshima S; Shinohara H; Kondo M; Yoshida K
Gastric Cancer; 2022 Mar; 25(2):422-429. PubMed ID: 34550490
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of ileus and carcinomatous peritonitis].
Ishido K; Koizumi W; Tanabe S; Higuchi K; Sasaki T; Katada C; Azuma M; Naruke A
Gan To Kagaku Ryoho; 2011 Apr; 38(4):509-14. PubMed ID: 21505272
[TBL] [Abstract][Full Text] [Related]
13. Medical Therapy of Malignant Bowel Obstruction With Octreotide, Dexamethasone, and Metoclopramide.
Berger J; Lester P; Rodrigues L
Am J Hosp Palliat Care; 2016 May; 33(4):407-10. PubMed ID: 25646530
[TBL] [Abstract][Full Text] [Related]
14. Gastric electrical stimulation: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(16):1-79. PubMed ID: 23074486
[TBL] [Abstract][Full Text] [Related]
15. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
Mystakidou K; Tsilika E; Kalaidopoulou O; Chondros K; Georgaki S; Papadimitriou L
Anticancer Res; 2002; 22(2B):1187-92. PubMed ID: 12168923
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
[TBL] [Abstract][Full Text] [Related]
17. Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer.
Watanabe H; Inoue Y; Uchida K; Okugawa Y; Hiro J; Ojima E; Kobayashi M; Miki C; Kusunoki M
J Pediatr Surg; 2007 Jan; 42(1):259-60. PubMed ID: 17208578
[TBL] [Abstract][Full Text] [Related]
18. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial.
Gebbia V; Testa A; Valenza R; Cannata G; Tirrito ML; Gebbia N
Cancer; 1995 Nov; 76(10):1821-8. PubMed ID: 8625054
[TBL] [Abstract][Full Text] [Related]
19. Palliative Management of Inoperable Malignant Bowel Obstruction: Prospective, Open Label, Phase 2 Study at an NCI Comprehensive Cancer Center.
Walter M; Hansen E; Hamid S; Carozza D; Mann G; Roche C; George A; Attwood K; Case A
J Pain Symptom Manage; 2024 Jan; 67(1):20-26. PubMed ID: 37769820
[TBL] [Abstract][Full Text] [Related]
20. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
